Lung Cancer in Women: The Differences in Epidemiology, Biology and Treatment Outcomes

Maria Patricia Rivera


Expert Rev Resp Med. 2009;3(6):627-634. 

In This Article

Five-year View

As most of the literature on this topic is retrospective, prospective evaluations of these differences in lung cancer epidemiology, biology, and treatment outcomes between men and women, particularly as they apply to clinical practice, are required. Screening for EGFR mutations is now warranted in women with lung cancer. Further studies evaluating the effects of growth factor receptors on lung cancer development and the impact HRT may have on lung cancer risk and mortality in women are needed.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.